Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Stroke Damage
Author Information
Author(s): Anna Murasheva, Oksana Fuks, Nataliya Timkina, Arina Mikhailova, Timur Vlasov, Konstantin Samochernykh, Tatiana Karonova
Primary Institution: Almazov National Medical Research Centre
Hypothesis
The study aims to investigate the neuroprotective effects of SGLT-2 inhibitors and GLP-1 receptor agonists on brain damage in stroke models.
Conclusion
SGLT-2 inhibitors and GLP-1 receptor agonists are neuroprotective in experimental stroke, with GLP-1 receptor agonists showing greater effectiveness in non-diabetic conditions.
Supporting Evidence
- All drugs reduced brain damage volume compared to control.
- Dulaglutide improved neurological status more than metformin.
- SGLT-2 inhibitors and GLP-1 receptor agonists decreased neuronal damage markers.
- Diabetic rats showed more pronounced neurological deficits without treatment.
Takeaway
This study shows that certain diabetes medications can help protect the brain during a stroke, especially in people without diabetes.
Methodology
The study involved non-diabetic and diabetic rats treated with different drugs before inducing stroke, followed by assessments of neurological status and brain damage.
Potential Biases
Potential bias in drug selection and treatment administration.
Limitations
The study was conducted in animal models, which may not fully replicate human conditions.
Participant Demographics
Male Wistar rats, both non-diabetic and diabetic.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website